FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

David Cunningham

Research Profile

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Co-author Network

Publications

TOP 3
A C Roy; J Tabernero; C G Yeh; M B Cardic; Y Chao; L T Chen; David Cunningham; Y K Kang; M Kujundzic; H Y Lim; S R Park; F J Ramos; C Rees; A de Gramont
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Tom Waddell; Jonathan Wadsley; Justin Waters; Andrew Wotherspoon; Ian Chau; Fareeda Coxon; Tom Crosby; David Cunningham; Stephen Falk; David Ferry; Alicia Frances; David Gonzalez; Tim Iveson; Wasat Mansoor; Gary Middleton; Clare Okines; Clare Peckitt; Claire Saffery; Sarah Slater; David Smith; Yolanda Barbachano
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Sonya Crowe; David Cunningham; Rodney Franklin; John Gibbs; Nagarajan Muthialu; Christina Pagel; Kate L Brown; Catherine Bull; Martin Utley; Victor T Tsang
Development of a diagnosis- and procedure-based risk model for 30-day outcome after pediatric cardiac surgery.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of David Cunningham (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: A C Roy; J Tabernero; C G Yeh; M B Cardic; Y Chao; L T Chen; David Cunningham; Y K Kang; M Kujundzic; H Y Lim; S R Park; F J Ramos; C Rees; A de Gramont
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2013;24(6):1567-73.
2013: Tom Waddell; Jonathan Wadsley; Justin Waters; Andrew Wotherspoon; Ian Chau; Fareeda Coxon; Tom Crosby; David Cunningham; Stephen Falk; David Ferry; Alicia Frances; David Gonzalez; Tim Iveson; Wasat Mansoor; Gary Middleton; Clare Okines; Clare Peckitt; Claire Saffery; Sarah Slater; David Smith; Yolanda Barbachano
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
The lancet oncology 2013;14(6):481-9.
2013: Sonya Crowe; David Cunningham; Rodney Franklin; John Gibbs; Nagarajan Muthialu; Christina Pagel; Kate L Brown; Catherine Bull; Martin Utley; Victor T Tsang
Development of a diagnosis- and procedure-based risk model for 30-day outcome after pediatric cardiac surgery.
The Journal of thoracic and cardiovascular surgery 2013;145(5):1270-8.
2013: Richard A Hubner; Fiona Worsnop; David Cunningham; Ian Chau
Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer.
Pancreas 2013;42(3):511-5.
2013: John Bridgewater; Pippa G Corrie; David Cunningham; Roopinder Gillmore; Mark Harrison; Tim Iveson; Daniel Palmer; Harpreet Wasan; Justin Waters; Juan Valle
Outcome of second-line chemotherapy for biliary tract cancer.
European journal of cancer (Oxford, England : 1990) 2013;49(6):1511.
2013: Anastasia Constantinidou; David Cunningham; Aamir Khan; Satvinder S Mudan; Sheela Rao; Fatima Shurmahi; Uzma Asghar; Yolanda Barbachano; Ian Chau
Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
Clinical colorectal cancer 2013;12(1):15-22.
2013: Sarah Payne; Danny Burke; David Cunningham; Johnathan Joffe; Alison Jones; Janine Mansi; Gordon McVie; Alison Norton; Roshan Agarwal
Discordance between cancer prevalence and training: a need for an increase in oncology education.
Clinical medicine (London, England) 2013;13(1):50-6.
2013: Elizabeth C Smyth; David Cunningham
Gastric cancer in 2012: Defining treatment standards and novel insights into disease biology.
Nature reviews. Clinical oncology 2013;10(2):73-4.
2012: Vikram K Jain; Andrew C Wotherspoon; Branislav Bystricky; Ian Chau; David Cunningham
Primary follicular lymphoma of the GI tract: an increasingly recognized entity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(36):e370-2.
2012: Eliza A Hawkes; Andrew Wotherspoon; David Cunningham
Diagnosis and management of rare gastrointestinal lymphomas.
Leukemia & lymphoma 2012;53(12):2341-50.
2012: Alicia F C Okines; David Cunningham
Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer.
Therapeutic advances in gastroenterology 2012;5(5):301-18.
2012: Elizabeth C Smyth; David Cunningham
Targeted therapy for gastric cancer.
Current treatment options in oncology 2012;13(3):377-89.
2012: A Roy; A Schalhorn; P Schoffski; H Sörbye; M Mousseau; Marianne Nicolson; O Rixe; R Rodriguez; A Adenis; G Adler; J Aparicio; J-R Barcelo; J-L Canon; J Cassinello; C Castanon; David Cunningham; Lionel D'Hondt; E Fonseca; C Garcia Giron; R Hawkins; D K Hossfeld; Joseph Kerger; Fiona J Lofts; G Lopez-Vivanco; J-L Misset
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
British journal of cancer 2012;107(3):435-41.
2012: Alice Dewdney; David Cunningham
Toward the non-surgical management of locally advanced rectal cancer.
Current oncology reports 2012;14(3):267-76.
2012: A Dewdney; David Cunningham; Yolanda Barbachano; Ian Chau
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection.
British journal of cancer 2012;106(11):1718-21.
2012: Alice Dewdney; Bengt Glimelius; David Gonzalez de Castro; Jacqueline Oates; Josep Tabernero; Diana Tait; Rachel Wong; Andrew Wotherspoon; Yolanda Barbachano; Gina Brown; Jaume Capdevila; Andres Cervantes; Yu Jo Chua; David Cunningham; Ian Chau
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(14):1620-7.
2012: Eliza A Hawkes; Andrew Wotherspoon; David Cunningham
The unique entity of nodular lymphocyte-predominant Hodgkin lymphoma: current approaches to diagnosis and management.
Leukemia & lymphoma 2012;53(3):354-61.
2012: Sarah Barton; Eliza A Hawkes; Andrew Wotherspoon; David Cunningham
Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
The oncologist 2012;17(12):1562-73.
2012: Eliza A Hawkes; George Ladas; Andrew G Nicholson; Sheela Rao; Gihan Ratnayake; Katharina Wassilew; Yolanda Barbachano; David Cunningham; Ian Chau
Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases.
BMC cancer 2012;12():326.
2012: Vikram K Jain; David Cunningham; Ian Chau
Preoperative and postoperative chemotherapy for gastric cancer.
Surgical oncology clinics of North America 2012;21(1):99-112.
2011: Vikram K Jain; Eliza A Hawkes; David Cunningham
Integration of biologic agents with cytotoxic chemotherapy in metastatic colorectal cancer.
Clinical colorectal cancer 2011;10(4):245-57.
2011: William H Allum; Jane M Blazeby; David Cunningham; S Michael Griffin; Janusz A Jankowski; Rachel Wong
Guidelines for the management of oesophageal and gastric cancer.
Gut 2011;60(11):1449-72.
2011: Jessica Evans; Kjell Pennert; Ian Swift; Diana Tait; Paris Tekkis; Andrew Wotherspoon; Ian Chau; David Cunningham; Gina Brown
Timing of surgery following preoperative therapy in rectal cancer: the need for a prospective randomized trial?
Diseases of the colon and rectum 2011;54(10):1251-9.
2011: Dorothy M Gujral; Maria Hawkins; Barbara Grilli Leonulli; Susan Ashley; Ian Chau; David Cunningham; Diana Tait
Nonsurgical management of esophageal adenocarcinoma.
Clinical colorectal cancer 2011;10(3):165-70.
2011: R Wong; A Wotherspoon; Yolanda Barbachano; G Brown; Y J Chua; S Compton; David Cunningham; T Hickish; A Khan; Satvinder S Mudan; C Saffery; A S Strimpakos; J Thomas; J Valle; Ian Chau
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(9):2042-8.
2011: Eliza A Hawkes; Diana Tait; Gina Brown; David Cunningham; Ian Chau
Neoadjuvant chemotherapy alone for early-stage rectal cancer: an evolving paradigm?
Seminars in radiation oncology 2011;21(3):196-202.
2011: Eliza Hawkes; Alicia F C Okines; Demetris Papamichael; Sheela Rao; Sue Ashley; Haris Charalambous; Alona Koukouma; Ian Chau; David Cunningham
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
European journal of cancer (Oxford, England : 1990) 2011;47(8):1146-51.
2011: Sheela Rao; Lyndsey Welsh; David Cunningham; Robert H te-Poele; Martin Benson; Andrew Norman; Claire Saffery; Ian Giddings; Paul Workman; Paul A Clarke
Correlation of overall survival with gene expression profiles in a prospective study of resectable esophageal cancer.
Clinical colorectal cancer 2011;10(1):48-56.
2011: R Baird; A Biondo; V Chhaya; J McLachlan; A Karpathakis; S Rahman; Yolanda Barbachano; David Cunningham; Ian Chau
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
British journal of cancer 2011;104(1):43-50.
2010: Uzma Asghar; Eliza Hawkes; David Cunningham
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer.
Clinical colorectal cancer 2010;9(5):274-81.
2010: Alicia Fc Okines; Alice Dewdney; Ian Chau; Sheela Rao; David Cunningham
Trastuzumab for gastric cancer treatment.
Lancet 2010;376(9754):1736; author reply 1736-7.
2010: Sheela Rao; N Starling; David Cunningham; Kate Sumpter; D Gilligan; T Ruhstaller; M Valladares-Ayerbes; H Wilke; C Archer; R Kurek; C Beadman; Jacqui Oates
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(11):2213-9.
2010: A F C Okines; David Cunningham
Multimodality treatment for localized gastro-oesophageal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21 Suppl 7():vii286-93.
2010: Alicia F C Okines; SE Ashley; David Cunningham; Jacqui Oates; Andrea Turner; Janine Webb; Claire Saffery; Yu Jo Chua; Ian Chau
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(25):3945-50.
2010: Alicia F C Okines; David Cunningham
Trastuzumab in gastric cancer.
European journal of cancer (Oxford, England : 1990) 2010;46(11):1949-59.
2010: Susana Banerjee; David Cunningham
Targeted therapies as adjuvant treatment for early-stage colorectal cancer: first impressions and clinical questions.
Clinical colorectal cancer 2010;9 Suppl 1():S28-35.
2010: A S Strimpakos; David Cunningham; C Mikropoulos; I Petkar; Yolanda Barbachano; Ian Chau
The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(5):1013-9.
2010: Alicia Okines; Bhupinder Sharma; David Cunningham
Perioperative management of esophageal cancer.
Nature reviews. Clinical oncology 2010;7(4):231-8.
2010: Madeleine Hewish; Christopher J Lord; Sarah A Martin; David Cunningham; Alan Ashworth
Mismatch repair deficient colorectal cancer in the era of personalized treatment.
Nature reviews. Clinical oncology 2010;7(4):197-208.
2010: David Cunningham; Wendy Atkin; Heinz-Josef Lenz; Henry T Lynch; Bruce Minsky; Bernard Nordlinger; Naureen Starling
Colorectal cancer.
Lancet 2010;375(9719):1030-47.
2010: Yu Jo Chua; Yolanda Barbachano; David Cunningham; Jacqui R Oates; Gina Brown; Andrew Wotherspoon; Diana Tait; Alison Massey; Niall C Tebbutt; Ian Chau
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
The lancet oncology 2010;11(3):241-8.
2010: Peter Broderick; David Cunningham; Jayaram Vijayakrishnan; Rosie Cooke; Alan Ashworth; Anthony Swerdlow; richard Houlston
IRF4 polymorphism rs872071 and risk of Hodgkin lymphoma.
British journal of haematology 2010;148(3):413-5.
2010: D J Watkins; Ian Chau; David Cunningham; Satvinder S Mudan; N Karanjia; Gina Brown; Sue Ashley; Andrew R Norman; A Gillbanks
Defining patient outcomes in stage IV colorectal cancer: a prospective study with baseline stratification according to disease resectability status.
British journal of cancer 2010;102(2):255-61.
2010: A F C Okines; U Asghar; David Cunningham; Sue Ashley; J Ashton; K Jackson; E Hawkes; Ian Chau
Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer.
Oncology 2010;79(1-2):150-8.
2009: Naureen Starling; David Watkins; David Cunningham; Janet Thomas; Janine Webb; Gina Brown; Karen Thomas; Jacqui Oates; Ian Chau
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5499-505.
2009: A Okines; O Del Puerto; David Cunningham; I Chau; E Van Cutsem; Leonard B Saltz; J Cassidy
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
British journal of cancer 2009;101(7):1033-8.
2009: Eliza Hawkes; Ian Chau; David H Ilson; David Cunningham
Upper gastrointestinal malignancies: a new era in clinical colorectal cancer.
Clinical colorectal cancer 2009;8(4):185-9.
2009: Alicia Okines; Yung-Jue Bang; David Cunningham
Accomplishments in 2008 in the management of localized gastric cancer.
Gastrointestinal cancer research : GCR 2009;3(5 Supplement 2):S48-52.
2009: Alicia Okines; David Cunningham
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
European journal of cancer (Oxford, England : 1990) 2009;45(14):2452-61.
2009: Naureen Starling; Sheela Rao; David Cunningham; Tim Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqui Oates; Andrew R Norman
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3786-93.
2009: Alex Leary; Laura Assersohn; David Cunningham; Andrew R Norman; Geoffrey Chong; Gina Brown; Paul J Ross; C Costello; L Higgins; Jacqui Oates
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Cancer chemotherapy and pharmacology 2009;64(3):455-62.
2009: Ian Chau; David Cunningham
Treatment in advanced colorectal cancer: what, when and how?
British journal of cancer 2009;100(11):1704-19.
2009: N Starling; A Okines; David Cunningham; William H Allum; Andrew Wotherspoon; M Benson; J Thompson; J Thomas; Gina Brown; A Riddell; F Stavridi; Sue Ashley; Jacqui Oates; Ian Chau
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
British journal of cancer 2009;100(11):1725-30.
2009: C Jackson; David Cunningham; J Oliveira
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():34-6.
2009: Ian Chau; Andrew R Norman; David Cunningham; Jacqui Oates; R Hawkins; Tim Iveson; Marianne Nicolson; P Harper; Matt Seymour; Tamas Hickish
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(5):885-91.
2009: Thomas Yau; David Watkins; David Cunningham; Yolanda Barbachano; Ian Chau; Geoffrey Chong
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
Diseases of the colon and rectum 2009;52(4):669-77.
2009: David Cunningham; Bhawna Sirohi; A Pluzanska; B Utracka-Hutka; J Zaluski; R Glynne-Jones; P Koralewski; J Bridgewater; PN Mainwaring; H Wasan; J-Y Wang; C Szczylik; P Clingan; R T T Chan; I Tabah-Fisch; J Cassidy
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(2):244-50.
2009: V Formica; Andrew R Norman; David Cunningham; Andrew Wotherspoon; Jacqui Oates; Geoffrey Chong
Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in assessing prognosis and predicting first-line treatment efficacy in follicular lymphoma patients.
Acta haematologica 2009;122(4):193-9.
2009: Madeleine Hewish; Ian Chau; David Cunningham
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
Recent patents on anti-cancer drug discovery 2009;4(1):54-72.
2008: N Starling; David Cunningham
Survival from cancer of the pancreas in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S24-5.
2008: Sheela Rao; David Cunningham
Survival from cancer of the stomach in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S19-20.
2008: Sheela Rao; David Cunningham
Survival from cancer of the oesophagus in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S14-5.
2008: Sheela Rao; N Starling; David Cunningham; M Benson; Andrew Wotherspoon; C Lüpfert; R Kurek; Jacqui Oates; José Baselga; A Hill
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
British journal of cancer 2008;99(6):868-74.
2008: Alicia Okines; Ian Chau; David Cunningham
Capecitabine in gastric cancer.
Drugs of today (Barcelona, Spain : 1998) 2008;44(8):629-40.
2008: David Cunningham; J Oliveira
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 2():ii23-4.
2008: Christopher Jackson; David Cunningham
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2008;44(5):652-62.
2008: David Cunningham; Naureen Starling; Sheela Rao; Tim Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqui Oates; Andrew R Norman
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
The New England journal of medicine 2008;358(1):36-46.
2008: Diletta Bianchini; Akali Jayanth; Yu Jo Chua; David Cunningham
Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Clinical colorectal cancer 2008;7(1):33-43.
2007: David Cunningham; Naureen Starling
Adjuvant chemotherapy of colorectal cancer.
Lancet 2007;370(9604):1980-1.
2007: Christopher Jackson; David Cunningham
A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Clinical colorectal cancer 2007;7 Suppl 1():S8-15.
2007: David Cunningham; Yu Jo Chua
East meets west in the treatment of gastric cancer.
The New England journal of medicine 2007;357(18):1863-5.
2007: David Watkins; David Cunningham
The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
Clinical colorectal cancer 2007;6 Suppl 2():S47-52.
2007: Yu Jo Chua; David Cunningham
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Annals of surgical oncology 2007;14(10):2687-90.
2007: Hendrik-Tobias Arkenau; Yu Jo Chua; David Cunningham
Current treatment strategies in elderly patients with metastatic colorectal cancer.
Clinical colorectal cancer 2007;6(7):508-15.
2007: V Formica; Andrew Wotherspoon; David Cunningham; Andrew R Norman; Bhawna Sirohi; Jacqui Oates; Geoffrey Chong
The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
British journal of cancer 2007;96(8):1178-82.
2007: Hendrik-Tobias Arkenau; Claire Gordon; Felicity Murphy; David Cunningham
Paraneoplastic syndrome: subacute cerebellar degeneration in Hodgkin's disease.
Leukemia & lymphoma 2007;48(4):819-22.
2007: Bhawna Sirohi; David Cunningham; Andy Norman; Kim Last; Ian Chau; Alan Horwich; Jacqui Oates; Geoffrey Chong; Andrew Wotherspoon
Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Hematology (Amsterdam, Netherlands) 2007;12(2):149-53.
2007: Ian Chau; David Cunningham; Tamas Hickish; Alison Massey; L Higgins; R Osborne; N Botwood; A Swaisland
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):730-7.
2007: Hendrik-Tobias Arkenau; Claire Gordon; David Cunningham; Andy Norman; Andrew Wotherspoon; Ian Chau
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
Leukemia & lymphoma 2007;48(3):547-50.
2007: Hendrik-Tobias Arkenau; Geoffrey Chong; David Cunningham; David Watkins; R Agarwal; Bhawna Sirohi; M Trumper; Andy Norman; Andrew Wotherspoon; Alan Horwich
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):541-5.
2007: Hendrik-Tobias Arkenau; Geoff Chong; David Cunningham; David Watkins; Bhawna Sirohi; Ian Chau; Andrew Wotherspoon; Andy Norman; Alan Horwich; Estella Matutes
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
Haematologica 2007;92(2):271-2.
2007: N Starling; D Tilden; J White; David Cunningham
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
British journal of cancer 2007;96(2):206-12.
2007: Christopher Jackson; Naureen Starling; Yu Jo Chua; David Cunningham
Pharmacotherapy for oesophagogastric cancer.
Drugs 2007;67(17):2539-56.
2006: Yu Jo Chua; David Cunningham
Panitumumab.
Drugs of today (Barcelona, Spain : 1998) 2006;42(11):711-9.
2006: Angela M Riddell; Julia Hillier; Gina Brown; D Michael King; Andrew C Wotherspoon; Jeremy N Thompson; David Cunningham; William H Allum
Potential of surface-coil MRI for staging of esophageal cancer.
AJR. American journal of roentgenology 2006;187(5):1280-7.
2006: N Starling; David Cunningham
The role of systemic therapy for localised gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x115-21.
2006: Ian Chau; David Cunningham
Adjuvant therapy in colon cancer--what, when and how?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(9):1347-59.
2006: David Cunningham; William H Allum; Sally P Stenning; Jeremy N Thompson; Cornelis J H van de Velde; Marianne Nicolson; John Howard Scarffe; Fiona J Lofts; Stephen J Falk; Tim Iveson; David B Smith; Ruth E Langley; Monica Verma; Simon Weeden; Yu Jo Chua
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
The New England journal of medicine 2006;355(1):11-20.
2006: M Trumper; Paul J Ross; David Cunningham; Andrew R Norman; R Hawkins; Matt Seymour; P Harper; Tim Iveson; Marianne Nicolson; Tamas Hickish
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
European journal of cancer (Oxford, England : 1990) 2006;42(7):827-34.
2006: Ian Chau; David Cunningham; C Russell; Andrew R Norman; Tom Kurzawinski; P Harper; Phillip Harrison; Gary Middleton; F Daniels; Tamas Hickish; J Prendeville; Paul J Ross; Belinda A Theis; R Hull; M Walker; N Shankley; B Kalindjian; Gordon D Murray; A Gillbanks; James W Black
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
British journal of cancer 2006;94(8):1107-15.
2006: Yu Jo Chua; David Cunningham
Chemotherapy for advanced pancreatic cancer.
Best practice & research. Clinical gastroenterology 2006;20(2):327-48.
2006: Catherine Burton; David C Linch; P Hoskin; Donald Milligan; Martin J S Dyer; B Hancock; P Mouncey; Paul Smith; Wendi Qian; Kenneth A MacLennan; Andrew Jack; A Webb; David Cunningham
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
British journal of cancer 2006;94(6):806-13.
2006: Yu Jo Chua; David Cunningham
Neoadjuvant treatment of unresectable liver metastases from colorectal cancer.
Clinical colorectal cancer 2006;5(6):405-12.
2006: Michael Dickinson; Andrew Wotherspoon; David Cunningham
Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma.
Leukemia & lymphoma 2006;47(3):553-6.
2006: G Chong; A Bhatnagar; David Cunningham; T M Cosgriff; P G Harper; W Steward; J Bridgewater; M Moore; J Cassidy; R Coleman; F Coxon; C H Redfern; J J Jones; R Hawkins; D Northfelt; Sunil Sreedharan; Frank H Valone; J Carmichael
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):437-42.
2006: Ian Chau; Gina Brown; David Cunningham; Diana Tait; Andrew Wotherspoon; Andrew R Norman; Niall Tebbutt; Mark Hill; Paul J Ross; Alison Massey; Jacqui Oates
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):668-74.
2005: Yu Jo Chua; David Cunningham
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Clinical colorectal cancer 2005;5 Suppl 2():S81-8.
2005: Nick R Maisey; Andrew R Norman; A Hill; Alison Massey; Jacqui Oates; David Cunningham
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
British journal of cancer 2005;93(7):740-3.
2005: Geoffrey Chong; J L B Dickson; David Cunningham; Andrew R Norman; Sheela Rao; ME Hill; T J Price; Jacqui Oates; Niall Tebbutt
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
British journal of cancer 2005;93(5):510-4.
2005: Catherine Burton; Paul Smith; G Vaughan-Hudson; Wendi Qian; P Hoskin; David Cunningham; B Hancock; David C Linch
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
British journal of haematology 2005;130(4):536-41.
2005: F V Negri; Andrew Wotherspoon; David Cunningham; Andrew R Norman; Geoffrey Chong; Paul J Ross
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1305-10.
2005: Yu Jo Chua; David Cunningham
Adjuvant treatment for resectable pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(20):4532-7.
2005: Ian Chau; Andrew R Norman; David Cunningham; Tim Iveson; Mark Hill; Tamas Hickish; Fiona J Lofts; Duncan I Jodrell; Andrew Webb; Diana Tait; Paul J Ross; Pat Shellito; Jacqueline R Oates
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1551-9.
2005: Matthew Ng; David Cunningham; Andrew R Norman
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
European journal of cancer (Oxford, England : 1990) 2005;41(11):1542-6.
2005: Kate Sumpter; Catherine Harper-Wynne; David Cunningham; Sheela Rao; Niall Tebbutt; Andrew R Norman; C Ward; Tim Iveson; Marianne Nicolson; Tamas Hickish; Mark Hill; Jacqui Oates
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
British journal of cancer 2005;92(11):1976-83.
2005: Sheela Rao; David Cunningham; R E Hawkins; ME Hill; D Smith; F Daniel; Paul J Ross; Jacqui Oates; Andrew R Norman
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
British journal of cancer 2005;92(9):1650-4.
2005: Naureen Starling; David Cunningham
Second-line therapy for advanced colorectal carcinoma.
Current oncology reports 2005;7(3):173-80.
2005: M Ng; J Waters; David Cunningham; Ian Chau; Alan Horwich; Mark Hill; Andrew R Norman; Andrew Wotherspoon; Daniel Catovsky
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
British journal of cancer 2005;92(8):1352-7.
2005: Ian Chau; Andrew R Norman; David Cunningham; Diana Tait; Paul J Ross; Tim Iveson; Mark Hill; Tamas Hickish; Fiona J Lofts; Duncan I Jodrell; Andrew Webb; Jacqueline R Oates
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):549-57.
2004: Ian Chau; Andrew R Norman; David Cunningham; Justin S Waters; C Topham; Gary Middleton; Mark Hill; Paul J Ross; R Katopodis; G Stewart; Jacqueline R Oates
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
British journal of cancer 2004;91(8):1453-8.
2004: Ourania Katopodis; Paul Ross; Andrew R Norman; Jacqui Oates; David Cunningham
Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2230-6.
2004: Sheela Rao; David Cunningham; T Price; ME Hill; Paul J Ross; Niall Tebbutt; Andrew R Norman; Jacqui Oates; P Shellito
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
British journal of cancer 2004;91(5):839-43.
2004: Lynny Yung; David Cunningham; B Hancock; Paul Smith; Kenneth A MacLennan; David C Linch; A McMillan
Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
British journal of cancer 2004;91(4):695-8.
2004: Sadaf Haque; Jillian Noble; Andrew Wotherspoon; Christopher Woodhouse; David Cunningham
MALT lymphoma of the foreskin.
Leukemia & lymphoma 2004;45(8):1699-701.
2004: Rohit Lal; James Dickson; David Cunningham; Ian Chau; Andrew R Norman; Paul J Ross; Clare Topham; Gary Middleton; Mark Hill; Jacqui Oates
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3023-31.
2004: Francesca Negri; Antonino Musolino; David Cunningham; Ugo Pastorino; George Ladas; Andrew R Norman
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy.
Clinical colorectal cancer 2004;4(2):101-6.
2004: E Mitry; Jean-Yves Douillard; E Van Cutsem; David Cunningham; E Magherini; D Mery-Mignard; L Awad; Philippe Rougier
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1013-7.
2004: Naureen Starling; David Cunningham
Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
Current opinion in oncology 2004;16(4):385-90.
2004: Ian Chau; Andrew R Norman; David Cunningham; Justin S Waters; Jacqui Oates; Paul J Ross
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2395-403.
2004: Ian Chau; Mark J Allen; David Cunningham; Andrew R Norman; Gina Brown; Hugo Ford; Niall Tebbutt; Diana Tait; Mark Hill; Paul J Ross; Jacqui Oates
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1420-9.
2004: James L B Dickson; David Cunningham
Systemic treatment of gastric cancer.
European journal of gastroenterology & hepatology 2004;16(3):255-63.
2004: Timothy J Price; Paul J Ross; Tamas Hickish; Diana Tait; Andrew R Norman; Hugo Ford; Gary Middleton; Kate Sumpter; Mark Hill; Jacqui Oates; David Cunningham
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Clinical colorectal cancer 2004;3(4):235-42.
2004: Nick R Maisey; Andy Norman; Yvonne Prior; David Cunningham
Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):48-52.
2004: Geoffrey Chong; David Cunningham
Oesophageal cancer: preoperative chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv87-91.
2004: Laura Assersohn; Gina Brown; David Cunningham; C Ward; Jacqui Oates; Justin S Waters; ME Hill; Andrew R Norman
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(1):64-9.
2003: Cheng Yeoh; Ian Chau; David Cunningham; Andrew R Norman; Mark Hill; Paul J Ross
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Clinical colorectal cancer 2003;3(2):102-7.
2003: Kate Sumpter; Catherine Harper-Wynne; David Cunningham; A Gillbanks; Andrew R Norman; Mark Hill
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2003;15(5):221-6.
2003: Helen J Mackay; Mark Hill; Chris Twelves; R Glasspool; T Price; S Campbell; Alison Massey; M A Macham; M Uzzel; S M Bailey; C Martin; David Cunningham
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1264-9.
2003: Ian Chau; R Jones; David Cunningham; Andrew Wotherspoon; Nick R Maisey; Andrew R Norman; PARESH JAIN; L Bishop; Alan Horwich; Daniel Catovsky
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
British journal of cancer 2003;89(1):36-42.
2003: A Saini; Andrew R Norman; David Cunningham; Ian Chau; Mark Hill; Diana Tait; Tamas Hickish; Tim Iveson; Fiona J Lofts; Duncan I Jodrell; Paul J Ross; Jacqui Oates
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
British journal of cancer 2003;88(12):1859-65.
2003: Niall Tebbutt; Andrew R Norman; David Cunningham; M Allen; Ian Chau; Jacqui Oates; Mark Hill
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
British journal of cancer 2003;88(10):1510-5.
2003: Ian Chau; Samuel Chan; David Cunningham
Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives.
Clinical colorectal cancer 2003;3(1):19-33.
2003: Laura Assersohn; Andrew R Norman; David Cunningham; Tim Iveson; Matt Seymour; Tamas Hickish; Alison Massey; Yvonne Prior; ME Hill
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1121-8.
2003: Ian Chau; M Allen; David Cunningham; Diana Tait; Gina Brown; Mark Hill; Kate Sumpter; A Rhodes; Andrew Wotherspoon; Andrew R Norman; A Hill; Alison Massey; Yvonne Prior
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
British journal of cancer 2003;88(7):1017-24.
2003: Ian Chau; Mark Harries; David Cunningham; Mark Hill; Paul J Ross; Caroline D Archer; Andrew R Norman; Andrew Wotherspoon; Dow-Mu Koh; Kairen Gill; Maggie Uzzell; Yvonne Prior; Daniel Catovsky
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
British journal of haematology 2003;120(6):970-7.
2003: Ian Chau; M T Kelleher; David Cunningham; Andrew R Norman; Andrew Wotherspoon; PA Trott; P Rhys-Evans; G Querci Della Rovere; Gina Brown; M Allen; Justin S Waters; S Haque; T Murray; L Bishop
Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients.
British journal of cancer 2003;88(3):354-61.
2003: Robin L Jones; David Cunningham
Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Clinical colorectal cancer 2003;2(4):235-8.
2003: Ian Chau; Anne Rigg; David Cunningham
Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
Critical reviews in oncology/hematology 2003;45(2):151-76.
2003: David C Farrugia; Hugo Ford; David Cunningham; Kathleen D Danenberg; Peter V Danenberg; Jan Brabender; A David McVicar; G Wynne Aherne; Anthea Hardcastle; Keith McCarthy; Ann L Jackman
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):792-801.
2003: S Rao; David Cunningham
Adjuvant therapy for colon cancer in the new millenium.
Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2003;92(1):57-64.
2003: A E Guppy; Niall Tebbutt; Andy Norman; David Cunningham
The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2003;44(1):123-5.
2002: Justin S Waters; Diana Tait; David Cunningham; AR Padhani; ME Hill; S Falk; Fiona J Lofts; Andy Norman; Jacqui Oates; A Hill
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(11):1763-70.
2002: Ian Chau; David Cunningham
Adjuvant therapy in colon cancer: current status and future directions.
Cancer treatment reviews 2002;28(5):223-36.
2002: Niall Tebbutt; Andy Norman; David Cunningham; Tim Iveson; Matt Seymour; Tamas Hickish; P Harper; Nick R Maisey; K Mochlinski; Yvonne Prior; Mark Hill
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(10):1568-75.
2002: Ian Chau; David Watkins; David Cunningham
Gemcitabine and its combinations in the treatment of malignant lymphoma.
Clinical lymphoma 2002;3(2):97-104.
2002: Nick R Maisey; Ian Chau; David Cunningham; Andy Norman; Matt Seymour; Tamas Hickish; Tim Iveson; Mary O'Brien; Niall Tebbutt; Angela Harrington; Mark Hill
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3130-6.
2002: Nick R Maisey; Andy Norman; M Watson; M J Allen; ME Hill; David Cunningham
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1351-7.
2002: David Cunningham; S Falk; D Jackson
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
British journal of cancer 2002;86(11):1677-83.
2002: Niall Tebbutt; E Cattell; R Midgley; David Cunningham; D Kerr
Systemic treatment of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(7):1000-15.
2002: Paul Ross; Marianne Nicolson; David Cunningham; J Valle; Matt Seymour; P Harper; T Price; H Anderson; Tim Iveson; Tamas Hickish; Fiona J Lofts; Andy Norman
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):1996-2004.
2002: Ian Chau; David Cunningham
Chemotherapy in colorectal cancer: new options and new challenges.
British medical bulletin 2002;64():159-80.
2002: Hugo Ford; Fraser Mitchell; David Cunningham; David C Farrugia; Mark E Hill; Charlotte Rees; A Hilary Calvert; Ian R Judson; Ann L Jackman
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):103-9.
2001: Ian Chau; Andrew Webb; David Cunningham; Mark Hill; Sheela Rao; S Ageli; Andy Norman; K Gill; A Howard; Daniel Catovsky
An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
British journal of haematology 2001;115(4):786-92.
2001: Ian Chau; Andrew Webb; David Cunningham; Mark Hill; Justin S Waters; Andy Norman; Alison Massey
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
British journal of cancer 2001;85(9):1258-64.
2001: David Cunningham; R Coleman
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cancer treatment reviews 2001;27(4):211-20.
2001: Nick R Maisey; David Cunningham
Current therapy and future prospects in lymphoma.
Expert review of anticancer therapy 2001;1(1):29-41.
2001: P N Mainwaring; David Cunningham; Walter Gregory; P Hoskin; B Hancock; A J Norton; Kenneth A MacLennan; Paul Smith; G V Hudson; David C Linch
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Blood 2001;97(10):2991-7.
2001: David Cunningham; R D James
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(7):826-34.
2001: J Waters; David Cunningham
The changing face of chemotherapy in colorectal cancer.
British journal of cancer 2001;84(1):1-7.
2000: Kate Sumpter; David Cunningham
Combination chemotherapy and colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):105-11.
2000: RK Gregory; David Cunningham; T A Fisher; P Rhys-Evans; G W Middleton; L Bishop; Andrew Wotherspoon; PA Trott; A G Nash
Investigating lymphadenopathy--report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital.
Postgraduate medical journal 2000;76(899):566-8.
2000: Hugo Ford; David Cunningham; Paul J Ross; Sheela Rao; G Wynne Aherne; T S Benepal; T Price; Alison Massey; L Vernillet; G Gruia
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
British journal of cancer 2000;83(2):146-52.
2000: JM Foran; RK Gupta; David Cunningham; R A Popescu; Anthony H Goldstone; J W Sweetenham; Ruth Pettengell; Peter WM Johnson; E Bessell; B Hancock; Karin E Summers; J Hughes; Ama Z S Rohatiner; T Andrew Lister
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
British journal of haematology 2000;109(1):81-8.
2000: Jean-Yves Douillard; David Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; Gabriela Gruia; L Awad; Philippe Rougier
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet 2000;355(9209):1041-7.
2000: Nick R Maisey; ME Hill; A Webb; David Cunningham; Glenn D Flux; AR Padhani; Robert J Ott; Andy Norman; L Bishop
Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
European journal of cancer (Oxford, England : 1990) 2000;36(2):200-6.
2000: JM Foran; David Cunningham; Bertrand Coiffier; Philippe Solal-Celigny; Felix Reyes; M Ghielmini; Peter WM Johnson; Christian Gisselbrecht; Michael Bradburn; Janet Matthews; T Andrew Lister
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():117-21.
2000: JM Foran; Ama Z S Rohatiner; David Cunningham; R A Popescu; Philippe Solal-Celigny; M Ghielmini; Bertrand Coiffier; Peter WM Johnson; Christian Gisselbrecht; Felix Reyes; John A Radford; E M Bessell; B Souleau; A Benzohra; T Andrew Lister
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):317-24.
1999: R A Popescu; A Norman; Paul J Ross; B Parikh; David Cunningham
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2412-8.
1999: RA Popescu; AC Wotherspoon; David Cunningham; Andy Norman; JA Prendiville; ME Hill
Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience.
European journal of cancer (Oxford, England : 1990) 1999;35(6):928-34.
1999: Paul J Ross; David Cunningham
The management of colorectal cancer: chemotherapy.
Critical reviews in oncology/hematology 1999;30(3):215-26.
1999: Justin S Waters; Andy Norman; David Cunningham; John Howard Scarffe; Andrew Webb; P Harper; Johnathan Keith Joffe; M Mackean; J Mansi; M Leahy; A Hill; Jacqui Oates; Sheela Rao; Marianne Nicolson; Tamas Hickish
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
British journal of cancer 1999;80(1-2):269-72.
1999: Laura Assersohn; Andy Norman; David Cunningham; T Benepal; P J Ross; Jacqui Oates
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
British journal of cancer 1999;79(11-12):1800-5.
1999: David Cunningham
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Seminars in oncology 1999;26(1 Suppl 5):1-5.
1998: David Cunningham; S Pyrhönen; R D James; C J Punt; T F Hickish; R Heikkila; T B Johannesen; H Starkhammar; Clare Topham; L Awad; C Jacques; P Herait
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Lancet 1998;352(9138):1413-8.
1998: C Crawley; P Ross; Andy Norman; A Hill; David Cunningham
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
British journal of cancer 1998;78(4):508-10.
1998: RA Popescu; AC Wotherspoon; David Cunningham
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Bone marrow transplantation 1998;22(1):103-6.
1998: D C Farrugia; Andrew R Norman; David Cunningham
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1998;34(7):987-91.
1998: H J N Andreyev; Andrew R Norman; David Cunningham; Jacqueline R Oates; Paul A Clarke
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
Journal of the National Cancer Institute 1998;90(9):675-84.
1998: RA Popescu; AC Wotherspoon; David Cunningham
Local recurrence of a primary pancreatic lymphoma 18 years after complete remission.
Hematological oncology 1998;16(1):29-32.
1998: H J N Andreyev; Andrew R Norman; Jacqui Oates; David Cunningham
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
European journal of cancer (Oxford, England : 1990) 1998;34(4):503-9.
1998: David Cunningham
Mature results from three large controlled studies with raltitrexed ('Tomudex').
British journal of cancer 1998;77 Suppl 2():15-21.
1997: Paul Ross; Andy Norman; David Cunningham; Andrew Webb; Tim Iveson; AR Padhani; JA Prendiville; M Watson; Alison Massey; RA Popescu; Jacqui Oates
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):995-1001.
1997: Paul J Ross; Andrew Webb; David Cunningham; JA Prendiville; Andrew R Norman; Jacqui Oates
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):111-5.
1997: Justin S Waters; Paul J Ross; R A Popescu; David Cunningham
New approaches to the treatment of gastro-intestinal cancer.
Digestion 1997;58(6):508-19.
1997: David Cunningham
Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
Tumori 1997;83(1 Suppl):S70-1.
1997: M P Findlay; David Cunningham; G Morgan; S Clinton; Anthea Hardcastle; G Wynne Aherne
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
British journal of cancer 1997;75(6):903-9.
1997: Andrew Webb; David Cunningham; John Howard Scarffe; P Harper; Andy Norman; Johnathan Keith Joffe; M Hughes; J Mansi; Michael Findlay; A Hill; Jacqui Oates; Marianne Nicolson; Tamas Hickish; M O'Brien; Tim Iveson; M Watson; Craig Underhill; Andrew M Wardley; M Meehan
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):261-7.
1996: D C Farrugia; Andrew R Norman; M C Nicolson; M Gore; E O Bolodeoku; Andrew Webb; David Cunningham
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
European journal of cancer (Oxford, England : 1990) 1996;32A(13):2256-61.
1996: David Cunningham; J R Zalcberg; U Rath; I Oliver; E van Cutsem; C Svensson; J F Seitz; P Harper; D Kerr; G Perez-Manga
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):961-5.
1996: Konstantinos Gossios; E V Tsianos; V Nicolson; A Bamias; David Cunningham; J Husband
CT evaluation of the resectability of gastric cancer postchemotherapy.
Abdominal imaging 1996;21(4):293-8.
1996: A Bamias; M E Hill; David Cunningham; Andrew R Norman; F Y Ahmed; Andrew Webb; M Watson; A S Hill; M C Nicolson; M E R O'Brien; T C Evans; V Nicolson
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Cancer 1996;77(10):1978-85.
1996: M E O'Brien; Sarah Milan; David Cunningham; A L Jones; Marianne Nicolson; P Selby; Tamas Hickish; M Hill; Martin E Gore; C Viner
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
British journal of cancer 1996;73(10):1272-7.
1996: Michael Findlay; H Young; David Cunningham; A Iveson; B Cronin; Tamas Hickish; B Pratt; J Husband; Maggie A Flower; R Ott
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):700-8.
1996: David Cunningham; John Zalcberg; I Smith; M Gore; R Pazdur; H Burris; N J Meropol; G Kennealey; L Seymour
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):179-82.
1996: Paul J Ross; Andrew Webb; David Cunningham; J Prendiville; Andrew R Norman; Jacqui Oates
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
The Journal of infusional chemotherapy 1996;6(3):141-4.
1996: Michael Findlay; F Raynaud; David Cunningham; A Iveson; David J Collins; Martin Leach
Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):47-53.
1996: P Ross; J Heron; David Cunningham
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 5():S13-7.
1996: Andrew Webb; P Scott-Mackie; David Cunningham; Andy Norman; J Andreyev; M O'Brien; J Bensted
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):63-8.
1995: H J N Andreyev; Andrew R Norman; David Cunningham; A R Padhani; A S Hill; Paul J Ross; Andrew Webb
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2209-14.
1995: David Cunningham; J R Zalcberg; U Rath; I Olver; E Van Cutsem; C Svensson; J F Seitz; P Harper; D Kerr; G Perez-Manga
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
European journal of cancer (Oxford, England : 1990) 1995;31A(12):1945-54.
1995: Marianne Nicolson; Andrew Webb; David Cunningham; Andy Norman; M O'Brien; A Hill; Tamas Hickish
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(8):801-4.
1995: M Hill; Andy Norman; David Cunningham; Michael Findlay; M Watson; V Nicolson; Andrew Webb; Gary Middleton; F Ahmed; Tamas Hickish
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2317-23.
1995: P A Ellis; Andy Norman; A Hill; M E O'Brien; Marianne Nicolson; Tamas Hickish; David Cunningham
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
European journal of cancer (Oxford, England : 1990) 1995;31A(10):1594-8.
1995: Andrew Webb; P Scott-Mackie; David Cunningham; Andy Norman; J Andreyev; M O'Brien; J Bensted
The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(6):581-7.
1995: H J N Andreyev; P Scott-Mackie; David Cunningham; V Nicolson; Andrew R Norman; S S Badve; A Iveson; M C Nicolson
Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1486-92.
1995: M Hill; Andy Norman; David Cunningham; Michael Findlay; V Nicolson; A Hill; A Iveson; C Evans; Johnathan Keith Joffe; Marianne Nicolson
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1297-302.
1995: A Bamias; David Cunningham; V Nicolson; Andy Norman; M Hill; Marianne Nicolson; M O'Brien; Andrew Webb; A Hill
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
British journal of cancer 1995;71(3):583-6.
1995: David Cunningham; M E Hill; M Watson; Andrew R Norman
Survival after systemic therapy for metastatic colorectal cancer.
Lancet 1995;345(8945):328-9.
1995: M Hill; Sarah Milan; David Cunningham; J Mansi; I Smith; D Catovsky; M Gore; G Zulian; P Selby; A Horwich
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):387-95.
1995: G Middleton; David Cunningham
Current options in the management of gastrointestinal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 1():17-25; discussion 25-6.
1995: M E O'Brien; David Cunningham
The role of chemotherapy for metastatic gastric cancer.
The Journal of infusional chemotherapy 1995;5(3):112-6.
1995: A E Taylor; V M Nicolson; David Cunningham
Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
British journal of cancer 1995;71(1):92-6.
1994: Michael Findlay; David Cunningham; Andy Norman; J Mansi; Marianne Nicolson; Tamas Hickish; V Nicolson; A Nash; N Sacks; H Ford
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):609-16.
1994: Tamas Hickish; D Robertson; P Clarke; M Hill; F di Stefano; C Clarke; David Cunningham
Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.
Cancer research 1994;54(10):2808-11.
1994: David Cunningham; L Paz-Ares; Martin E Gore; J Malpas; Tamas Hickish; Marianne Nicolson; M Meldrum; C Viner; Sarah Milan; Peter J Selby
High-dose melphalan for multiple myeloma: long-term follow-up data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):764-8.
1994: David Cunningham; L Paz-Ares; Sarah Milan; R Powles; Marianne Nicolson; Tamas Hickish; P Selby; J Treleavan; C Viner; J Malpas
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):759-63.
1994: Michael Findlay; A Hill; David Cunningham; Andy Norman; Marianne Nicolson; H Ford; J Husband; C Evans; R Carter
Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):239-43.
1993: M Hill; David Cunningham; D MacVicar; A Roldan; J Husband; R McCready; J Mansi; Sarah Milan; Tamas Hickish
Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2273-8.
1993: J L Mansi; David Cunningham; C Viner; E Ellis; M Meldrum; Sarah Milan; M Gore
Repeat administration of high dose melphalan in relapsed myeloma.
British journal of cancer 1993;68(5):983-7.
1993: Tamas Hickish; David Cunningham; Kay W Colston; B C Millar; J Sandle; A G Mackay; M Soukop; J Sloane
The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.
British journal of cancer 1993;68(4):668-72.
1993: Tamas Hickish; A Roldan; David Cunningham; J Mansi; Sue Ashley; V Nicolson; M E Gore; D Catovsky; Ian E Smith
EPIC: an effective low toxicity regimen for relapsing lymphoma.
British journal of cancer 1993;68(3):599-604.
1993: Michael Findlay; Martin Leach; David Cunningham; David J Collins; Geoffrey S Payne; J Glaholm; J L Mansi; V Ralph McCready
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):597-602.
1993: M Findlay; David Cunningham
Current advances in the treatment of gastrointestinal malignancy.
Critical reviews in oncology/hematology 1993;14(2):127-52.
1993: David Cunningham; M Findlay
The chemotherapy of colon cancer can no longer be ignored.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2077-9.
1993: Tamas Hickish; P Serafinowski; David Cunningham; Amit Oza; E Dorland; I Judson; B C Millar; T A Lister; A Roldan
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
British journal of cancer 1993;67(1):139-43.
1992: J Mansi; F da Costa; C Viner; I Judson; M Gore; David Cunningham
High-dose busulfan in patients with myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1569-73.
1992: J Mansi; E Ellis; C Viner; J Mundy; T Smith; J Millar; Sarah Milan; M Gore; David Cunningham
Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.
Cancer chemotherapy and pharmacology 1992;30(2):149-51.
1991: Tamas Hickish; H Purvies; J Mansi; M Soukop; David Cunningham
Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
British journal of cancer 1991;64(6):1161-3.
1991: J B Bell; A Montes; RP Gooding; P Riches; David Cunningham; B C Millar
Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
Leukemia 1991;5(11):958-61.
1991: A L Jones; A S Hill; M Soukop; A W Hutcheon; J Cassidy; Stanley B Kaye; K Sikora; D N Carney; David Cunningham
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Lancet 1991;338(8765):483-7.
1990: J B Bell; B C Millar; A Montes-Borinaga; Johnathan Keith Joffe; David Cunningham; J Mansi; Jennifer Treleaven; C Viner; T J McElwain
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
Hematological oncology 1990;8(6):347-53.
1988: David Cunningham; C J Bradley; G J Forrest; A W Hutcheon; L Adams; M Sneddon; M Harding; D J Kerr; M Soukop; Stanley B Kaye
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
European journal of cancer & clinical oncology 1988;24(4):685-9.
1987: David Cunningham; A Hepplestone; N L Gilchrist; J H Dagg; I L Evans; M Soukop
Failure of conventional chemotherapy in aggressive lymphomas.
Postgraduate medical journal 1987;63(735):11-5.
1986: David Cunningham; M Soukop; J F Stuart; A Setanoians; N L Gilchrist; G J Forrest; Stanley B Kaye
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
European journal of cancer & clinical oncology 1986;22(11):1325-9.
1986: David J Kerr; Stanley B Kaye; J Graham; Jim Cassidy; M Harding; A Setanoians; J C McGrath; W R Vezin; David Cunningham; G Forrest
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Cancer research 1986;46(6):3142-6.
1986: David Cunningham; M Soukop; N L Gilchrist; G J Forrest; D C Carter; C S McArdle; Stanley B Kaye; J W Dobbie; M Smith
TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage.
Medical oncology and tumor pharmacotherapy 1986;3(1):25-8.
1986: Jeff Cummings; G J Forrest; David Cunningham; N L Gilchrist; M Soukop
Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.
Cancer chemotherapy and pharmacology 1986;17(1):80-4.
1986: David Cunningham; N L Gilchrist; F D Lee; M Haxton; A Heppleston; G J Forrest; M Soukop
T-cell lymphoblastic lymphoma of the uterus complicated by Chlamydia trachomatis pneumonia.
Postgraduate medical journal 1986;62(723):55-7.
1986: David Cunningham; L McTaggart; M Soukop; Jeff Cummings; G J Forrest; J F Stuart
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Medical oncology and tumor pharmacotherapy 1986;3(2):95-9.
1985: David Cunningham; N L Gilchrist; R A Cowan; G J Forrest; C S McArdle; M Soukop
Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas.
British medical journal (Clinical research ed.) 1985;291(6503):1153-5.
1985: David Cunningham; G J Forrest; M Soukop; N L Gilchrist; I T Calder; C S McArdle
Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;291(6499):864-5.
1985: David Cunningham; N L Gilchrist; G J Forrest; M Soukop
Onycholysis associated with cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;290(6469):675-6.
1985: S Banham; A Dorward; A Hutcheon; S Ahmedzai; David Cunningham; A Burnett; M Soukop; N Lucie; S Kaye
The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
Seminars in oncology 1985;12(1 Suppl 2):2-6.
1985: David Cunningham; M Soukop; N L Gilchrist; G J Forrest; A Hepplestone; I T Calder; C S McArdle; A W Hutcheon; Stanley B Kaye
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;290(6468):604-5.
1985: N L Gilchrist; J Caldwell; ian watson; David Cunningham; G J Forrest; M Soukop; M Stewart; W Fitch
Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma.
Cancer chemotherapy and pharmacology 1985;15(3):290-4.
1985: David Cunningham; S W Banham; A H Hutcheon; A Dorward; S Ahmedzai; P Tansey; M Soukop; R D Stevenson; B R Stack; S B Kaye
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.
Cancer chemotherapy and pharmacology 1985;15(3):303-6.
1984: David Cunningham; M Soukop; C S McArdle; D C Carter; J F Smyth; S G Allan; Stanley B Kaye; G Sangster; K C Calman; A W Hutcheon
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
The British journal of surgery 1984;71(9):673-6.
1983: A W Hutcheon; J B Palmer; M Soukop; David Cunningham; C McArdle; J Welsh; F Stuart; G Sangster; S Kaye; D Charlton
A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
European journal of cancer & clinical oncology 1983;19(8):1087-90.